

## Media Release – For Immediate Distribution

### **InSphero Strengthens Scientific Advisory Board with Three Key Appointments to Advance Drug Discovery and Safety Solutions**

*New SAB members bring rich experience and expertise in human disease modeling and translational toxicology as well as a keen interest in 3D in vitro technologies.*

**Schlieren, Switzerland – November 24, 2020** InSphero AG, the pioneer of 3D cell-based assay technology, today announced the strengthening of its Scientific Advisory Board (SAB) with the appointment of Professors Thomas Hartung, MD PhD, Matthias von Herrath, MD, and Gerd Kullak-Ublick, MD.

“We are pleased to welcome these distinguished researchers to our SAB,” says InSphero CEO and co-founder Jan Lichtenberg, PhD. “They are all leading experts in their respective fields and will provide invaluable insights as we continue to advance our tailored drug development efforts at the forefront of preclinical research, with an emphasis on metabolic diseases, diabetes, oncology, and safety programs.”

**Prof. Hartung** is a Professor of Evidence-based Toxicology and Director of the Center for Alternatives to Animal Testing at Johns Hopkins University, and Professor of Pharmacology and Toxicology at the **University of Konstanz**. He is a passionate advocate for replacing animal testing with more ethical and predictive *in vitro* models and is investigating new applications for big data and artificial intelligence in toxicity testing.

**Prof. von Herrath** holds a dual appointment as Vice President and Senior Medical Officer at Novo Nordisk and Professor at the **La Jolla Institute for Immunology** Center for Autoimmunity and Inflammation. One of the world’s leading type 1 diabetes researchers, he is committed to clinical translation of immune-based interventions in autoimmune and metabolic diseases.

**Prof. Kullak-Ublick** is a Full Professor and Director of the Department of Clinical Pharmacology and Toxicology at the **University Hospital Zurich**. His primary research interests include function and regulation of drug transporters, new biomarkers of drug safety, and drug-induced liver and kidney injury. Prof. Kullak-Ublick’s contributions in the fields of pharmacology, toxicology, gastroenterology, and hepatology have received critical acclaim and recognition from honorable subject experts around the world.

InSphero Chief Scientific Officer, Prof. Armin Wolf, PhD, who looks forward to engaging and productive discussions with these new SAB members, says, “Visionary science has always been a driving force for InSphero innovation in drug discovery and safety. Our SAB will not only guide us, but also serve as a sparring partner to challenge us and bring added value to our collaborative research partnerships with leading pharma and biotech organizations.”

For more information about InSphero Leadership, visit <https://insphero.com/leadership>.

## InSphero Contact

Dr. Frank Junker  
Chief Business Officer  
Phone +41 44 5150490  
[frank.junker@insphero.com](mailto:frank.junker@insphero.com)

## About InSphero

InSphero is the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology *in vitro*. Its robust and precisely engineered suite of 3D InSight™ human tissue platforms are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company's 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development.

Learn more at [www.insphero.com](http://www.insphero.com) and follow us on [Twitter](#) and [LinkedIn](#).

## Images

